Basic Information
Ranexa (previously Latixa)
Regulatory Information
EMEA/H/C/000805
July 8, 2008
23
April 10, 2024
Company Information
Luxembourg
Menarini International Operations Luxembourg S.A. 1, Avenue de la Gare L-1611 Luxembourg
MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A.
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ranexa is indicated as add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line anti-anginal therapies (such as beta-blockers and / or calcium antagonists).
Overview Summary
This is a summary of the European public assessment report (EPAR). It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach its recommendations on how to use the medicine. If you need more information about your medical condition or your treatment, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. If you want more information on the basis of the CHMP recommendations, read the scientific discussion (also part of the EPAR).